APA

Jakubowiak A. J., Siegel D. S., Martin T., Wang M., Vij R., Lonial S., Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F., Reu F. J., Somlo G., Zonder J., Song K., Stewart A. K., Stadtmauer E., Harrison B. L., Wong A. F., Orlowski R. Z. & Jagannath S. (20140310). Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. : Leukemia.

Chicago

Jakubowiak A J, Siegel D S, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F J, Somlo G, Zonder J, Song K, Stewart A K, Stadtmauer E, Harrison B L, Wong A F, Orlowski R Z and Jagannath S. 20140310. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. : Leukemia.

Harvard

Jakubowiak A. J., Siegel D. S., Martin T., Wang M., Vij R., Lonial S., Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F., Reu F. J., Somlo G., Zonder J., Song K., Stewart A. K., Stadtmauer E., Harrison B. L., Wong A. F., Orlowski R. Z. and Jagannath S. (20140310). Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. : Leukemia.

MLA

Jakubowiak A J, Siegel D S, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F J, Somlo G, Zonder J, Song K, Stewart A K, Stadtmauer E, Harrison B L, Wong A F, Orlowski R Z and Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. : Leukemia. 20140310.